Analysis to Include Epidemiology and Primary Research with Urologists and Oncologists to Guide Pharmaceutical Companies in Understanding Opportunities and Challenges of the Bladder Cancer Drug Market
BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, will release a market forecast of the bladder cancer drug-treated population in the United States, France, Germany, Italy, Spain and the United Kingdom in its upcoming Bladder Cancer report. A peak-year sales forecast will also be provided for emerging bladder cancer therapies expected to launch before 2020, such as Allergan/Spectrum Pharmaceuticals’ EOquin and Novartis’s dovitinib.
To help pharmaceutical companies manufacturing drugs that treat bladder cancer to better understand the opportunities and challenges of the bladder cancer market, Decision Resources’ analysis will also include epidemiology as well as primary research with urologists and oncologists. The report provides a complete view of the market with detailed patterns of care segmented by patients with non-muscle-invasive, muscle-invasive and metastatic bladder cancer. Also addressed in the report are improved diagnostic techniques that have been adopted in recent years including fluorescence cystoscopy, urinary cytology and CT imaging, along with devices used to improve the delivery of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer.
“This report provides detailed analysis of the competitive landscape of the bladder cancer market,” said Analyst Mary Argent-Katwala, Ph.D. “In addition to the market forecast and primary research with country-specific thought leaders, analysis includes detailed coverage of patient populations, current therapies, unmet needs and emerging therapies.”
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
CONTACT:
Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources Group
Christopher Comfort, 781-993-2597
[email protected]
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical Other Health Research Science
MEDIA:
| Logo |